Evolution of a truncated nucleocapsid protein enhances SARS-CoV-2 fitness by suppressing antiviral responses
PLOS Biology · 2026
DOI: 10.1371/journal.pbio.3003646 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Biology, 2026. Verfasst von Rory P Mulloy und 7 weiteren Autor:innen. Beteiligte Einrichtung: Microbiology, Immunology and Infectious Diseases Department, Snyder Institute for Chronic Diseases, Charbonneau Cancer Research Institute, Cumming Sc…. Hauptthemen laut MEDLINE: SARS-CoV-2, Coronavirus Nucleocapsid Proteins, COVID-19. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Snyder Institute of Chronic Disease, Canadian Institutes of Health Research, Cumming School of Medicine.
Abstract (Originalsprache)
Viruses face selective pressure to evade cellular antiviral responses to control the outcome of an infection. However, due to their limited genome size, viruses must adopt unique strategies to confront cellular sensors. Since its emergence in humans, SARS-CoV-2 accrued many mutations; however, the functional consequence of many such genetic changes remains unexplored. Here, we show that SARS-CoV-2 produces a truncated form of the nucleocapsid protein, called N* M210 . Due to the acquisition of a viral transcription regulatory sequence (TRS) in the N gene, certain variants like Omicron produce a new viral mRNA that markedly increases N* M210 production. We show that N* M210 is a double-stranded RNA (dsRNA)-binding protein. Using its dsRNA binding motif, N* M210 inhibits multiple antiviral responses, supressing interferon, triggering processing body disassembly, and potently blocking G3BP1 foci, including stress granules and RNase L-dependent bodies. Using a panel of recombinant SARS-CoV-2 viruses (rSARS-2), we show that enhanced N* M210 production increases virus fitness in primary human cells and in mice. Furthermore, we show that during infection N* M210 improves virus fitness, in part, due to its ability to potently block G3BP1 foci. We propose a model where, to evade the cellular antiviral response, SARS-CoV-2 has evolved a mechanism to increase the production of a truncated form of the N protein, which limits activation of dsRNA-induced antiviral responses, tipping the balance in favor of the virus in the battle for control of the cell.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Microbiology, Immunology and Infectious Diseases Department, Snyder Institute for Chronic Diseases, Charbonneau Cancer Research Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
- Axe Maladies Infectieuses et Immunitaires, Centre de Recherche du CHU de Québec-Université Laval, Québec, Canada.
- Department of Microbiology, Infectious Disease and Immunology, Faculty of Medicine, Université Laval, Québec, Canada.
ORCID-Profile: Jennifer A Corcoran
Förderung
- Snyder Institute of Chronic Disease
- Canadian Institutes of Health Research
- Cumming School of Medicine
- Alberta Graduate Excellence Scholarship
- Institute of Infection and Immunity
Zitieren
APA
Mulloy, R. P., Evseev, D., Sharlin, N., Bui-Marinos, M. P., Lacasse, É., Dubuc, I., Flamand, L., & Corcoran, J. A. (2026). Evolution of a truncated nucleocapsid protein enhances SARS-CoV-2 fitness by suppressing antiviral responses. PLOS Biology. https://doi.org/10.1371/journal.pbio.3003646
Vancouver
Mulloy RP, Evseev D, Sharlin N, Bui-Marinos MP, Lacasse É, Dubuc I, et al. Evolution of a truncated nucleocapsid protein enhances SARS-CoV-2 fitness by suppressing antiviral responses. PLOS Biology. 2026. doi:10.1371/journal.pbio.3003646
BibTeX
@article{Mulloy2026,
author = {Mulloy, Rory P and Evseev, Danyel and Sharlin, Noga and Bui-Marinos, Maxwell P and Lacasse, Émile and Dubuc, Isabelle and Flamand, Louis and Corcoran, Jennifer A},
title = {Evolution of a truncated nucleocapsid protein enhances SARS-CoV-2 fitness by suppressing antiviral responses},
journal = {PLOS Biology},
year = {2026},
doi = {10.1371/journal.pbio.3003646}
}
EUVIMED